Korea Investment Corp I Mab Transaction History

Korea Investment Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$8.27 - $18.43 $187,729 - $418,361	-22,700 Reduced 41.8%	31,600 $357,000
Q1 2022 May 13, 2022	BUY	$12.54 - $46.93 $279,642 - $1.05 Million	22,300 Added 69.69%	54,300 $882,000
Q4 2021 Feb 09, 2022	SELL	$45.28 - $74.5 $63,392 - $104,300	-1,400 Reduced 4.19%	32,000 $1.52 Million
Q3 2021 Nov 12, 2021	BUY	$57.18 - $84.43 $11,436 - $16,886	200 Added 0.6%	33,400 $2.42 Million
Q2 2021 Aug 12, 2021	BUY	$47.86 - $83.95 $1.59 Million - $2.79 Million	33,200 New	33,200 $2.79 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $77.3M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Korea Investment Corp, based on Form 13F filings with the SEC.

Stay updated on Korea Investment Corp with notifications on news.